Carisma Therapeutics Inc.

Carisma Therapeutics, Inc. is a biotechnology company focused on developing transformative therapies for liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trials for liver fibrosis, and CT-1119, a mesothelin-targeted CAR-Monocyte in Phase I clinical trials for advanced mesothelin-positive solid tumors, including pancreatic, ovarian, lung, and mesothelioma cancers. The company also develops in vivo CAR-M cell therapy for solid tumors, including hepatocellular carcinoma. It has a collaboration and license agreement with ModernaTX, Inc. for oncology gene therapies. Formerly known as CARMA Therapeutics Inc., it changed its name to Carisma Therapeutics, Inc. in May 2017. Founded in 2016, it is headquartered in Philadelphia, Pennsylvania.